Kornimate/medical-research-clean huggingface dataset:
the helios heart registry: a standardized registry for patients with specific cardiac diseases

Conditions: Heart Failure; Coronary Artery Disease; Atrial Fibrillation

Summary: investigator-initiated, prospective, non-randomized, open label, non-interventional multicenter registry to evaluate current treatment of three major cardiovascular disease entities in clinical practice using a standardized variable-set of relevant covariates and outcome measures.

heart failure (hf), coronary artery disease (cad) and atrial fibrillation (af) are among the most relevant cardiovascular diseases contributing to overall morbidity and mortality each itself and in particular in case of their coexistence. several new therapies have been introduced in randomized controlled trials but confirmation data of treatment effects in real-world cohorts using a standardized methodology is scarce. the international consortium for health outcomes measurement (ichom) defined standard variable sets for all three diseases in order to objectively monitor the course of disease. to evaluate current health care utilization and interactions between diseases and treatments in patients with hf, cad and af as well as patient-oriented values study initiator will build a prospective, observational, multicenter cardiovascular registry using standardized patient variables and endpoints based on the ichom recommendations.

Eligibility criteria:
inclusion criteria: * age of 18 years or older * inpatient treatment * present diagnosis of at least one of the three cardiovascular disease entities of interest according to the current guidelines of the european society of cardiology (esc): hf, cad, af exclusion criteria: * inability to provide informed consent * initial presentation (index hospitalization) in cardiogenic shock or other kinds of shock * patient after heart transplantation or patient with present ventricular assist device (vad)

Keywords: cardiovascular disease hf cad af ichom
pilot trial of intravenous vitamin c in refractory non-hodgkin lymphoma (nhl)

Conditions: Non-Hodgkin Lymphoma

Summary: eligible candidates will be adults with aggressive or very aggressive nhl (who classification diagnosis confirmed by histological tumor examination). patients must have failed one or more prior nhl chemotherapy or antibody therapy with curative intent, and the disease must not have progressed within 60 days of last therapy. in addition, patients must not be candidates for potentially curative therapy, such as hsct, or they must have refused these alternative therapies. full inclusion/exclusion criteria are available. history and physical examination, and laboratory and imaging analyses will be done within 14 days prior to registration. intravenous ascorbic acid will be given in a dose based on the plasma vitamin c level to reach a level in the range of 300 to 350 mg/dl. vitamin c infusions will be given three times a week on a schedule that allows at least 24 hours between each infusion, for a total of ten weeks (30 infusions). if disease progression occurs before or at the ten week assessment, then we discontinue protocol, based on futility. toxicity and adverse events also will result in immediate discontinuation (details available in full protocol). if there is lack of disease progression or disease improvement, proceed and reassess again at 10 week intervals, for a total of three 10 week intervals. initial criteria are based upon the criteria from the international workshop to standardize criteria for non-hodgkin's lymphoma (cheson et al., report of an international workshop to standardize response criteria for non-hodgkin's lymphoma, journal of clinical oncology, 1999, vol. 17, no4, 1244-1253); response for this study will utilize pet in accordance with revised criteria (cheson et al. revised response criteria for malignant lymphoma. j of clin oncol 2007; 25(5): 579-586). we select 20 patients as an appropriate study size to evaluate a true response rate to therapy, compared to just the observed response.


Eligibility criteria:
inclusion criteria: * age greater than 18 years old * aggressive or very aggressive nhl * failed one or more therapies * patients must not have progressed within 60 days of last therapy * not received allogeneic stem cell transplant * no reasonable standard therapeutic options available * glucose 6 phosphate dehydrogenase status normal * ecog performance status 0-2 * normal creatinine and transaminase * women of child-bearing potential confirm negative pregnancy test exclusion criteria: * significant co-morbid disorders * significant psychiatric symptoms * smoking * excessive alcohol or drug use * enrollment in other experimental therapy * active infection * patients experiencing ongoing response to recent treatments * patients who have received chemotherapy within 30 days or biological therapy within 6 weeks
incidence and risk factors for tsih

Conditions: Incisional Hernia

Summary: trocar site incisional hernia (tsih) is the most frequent complication associated to laparoscopic surgery. few studies currently describes its real prevalence or risk factors. the aim of this study is to determine the real incidence of tsih and to identify risk factors in the investigator's series of patients. a cross sectional, prospective study is performed including consecutive patients who underwent a laparoscopic procedure during a four months period. all the patients are assessed both clinically (tsihc) and by an ultrasonographic exam (tsihu). main variable studied is the incidence of tsih. a multivariate analysis is performed to identify risk factors.

single-centre cross-sectional study based on prospective clinical and radiological assessment and retrospective risk factor analyses performed at a single hospital. all consecutive patients who underwent laparoscopic surgery (cholecystectomy, colon resection, adrenalectomy, nissen fundoplication and appendectomy) during a four months period were included in the study. at least 30 months after hospital discharge, they were invited by telephone to participate in the study. detailed project information was provided, and those who accepted received an appointment for an outpatient visit and a dynamic ultrasound. informed consent was obtained from all participants. in all patients, the umbilical trocar wound was closed with an interrupted suture with synthetic braided absorbable 2/0 suture (novosyn® or safil®). during the postoperative outpatient visit, clinical and ultrasonographic examinations were performed. to increase study homogeneity, all clinical examinations and ultrasounds were performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively. sonography was performed with an applio 500 equipment (toshiba, japan) with a 3.5mhz convex probe and a 7mhz linear probe. the ultrasound diagnosis was based on the identification of an abdominal wall defect with intraabdominal tissue protrusion. the main variables of the study were clinical (tsihc) and ultrasound (tsihu) diagnosis of incisional hernia. all results and variables were introduced in a previous specifically designed database (file makerpro 11.0v3 © 1984-2011 filemaker, inc.). data were collected from clinical interviews, physical and radiological examinations and the electronic medical record. statistical analyses were performed using the spss statistical software (ibm spss® statistics).

Eligibility criteria:
inclusion criteria: * previous laparoscopic surgery * age ≥18 years * informed consent signed exclusion criteria: * previous umbilical hernia repair * age \< 18 years * informed consent not signed * failure to attend the postoperative appointment

Keywords: incisional hernia port site trocar site risk factors incidence
stanford accelerated recovery trial (start)

Conditions: Pain; Breast Cancer; Lung Cancer

Summary: the goal of this study is to determine whether administering gabapentin prior to surgery affects duration of pain and opioid use post-surgery. the investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.

gabapentin was originally developed as an anti-convulsant, but was quickly recognized as a medication with significant analgesic activity in patients with neuropathic pain. more recently it has begun to be appreciated that it may have some benefits in the peri-operative period. pre-operative gabapentin reduces preoperative anxiety, early post-operative pain severity, post-operative opioid use and post-operative delirium (presumably through reduced opioid consumption). these same attributes are shared by medications such as nsaids and tylenol and the use of peri-operative gabapentin has not permeated the standard of care. early post-operative pain severity and preoperative anxiety have been implicated in our own research as risk factors for prolonged time to pain resolution and prolonged time to opioid cessation. since these endpoints are generally synonymous with time to recovery, interventions reducing these times would be seen not just to increase comfort but to actually speed recovery.

Eligibility criteria:
inclusion criteria * age 18 to 75 * undergoing a scheduled surgery * english speaking * ability and willingness to complete questionnaires or use palm pilot exclusion criteria * known kidney disease * currently receiving gabapentin or (pregabalin) lyrica already * cognitive impairment * previous history of excessive sedation or adverse reaction to gabapentin (not it was tried but ineffective for nerve pain) * coexisting chronic pain \> 4/10 disorder in area other than surgical target * plan to move out of state * condition that would in judgment of team member make patient likely to be lost to follow-up * elevated suicidality * known pregnancy * current symptoms of ataxia, dizziness, or sedation * narrow angle glaucoma * severe respiratory insufficiency (ie, severe emphysema or chronic obstructive pulmonary disease) * history of gastric bypass surgery and obstructive sleep apnea requiring continuous positive airway pressure (cpap)
improving practice patterns for the treatment of hypertension

Conditions: Hypertension

Summary: to improve the quality of hypertension care in our facility, while concurrently, examining the relative contribution of each aspect of a multi-factorial intervention designed to improve hypertension care.

this project was a randomized trial designed to examine the relative contribution of three quality improvement interventions of increasing intensity on bp control in veterans. providers in each stratum and their eligible patients were randomized to one of three study arms. the providers randomized to the first arm received education alone, and were considered the controls. providers randomized to the second arm received both provider education and a hypertension alert. the third arm included provider education, a hypertension alert, and patient education. patients were eligible for inclusion if they were aged 21- 90 years and filled their medications with the va pharmacies. between july and december 2003, we determined patient eligibility using a search strategy using data from the mid south quality improvement data warehouse, which is downloaded monthly from veterans' health information system and technology architecture (vista).

Eligibility criteria:
inclusion criteria: patients were eligible for inclusion if they were aged 21- 90 years and filled their medications with the va pharmacies. seen in 2003 and had a primary care visit coded as hypertension using international classification of diseases ninth revision; clinical modification (icd 9-cm) (24) of 401.1 or 401.9 and who were prescribed only one antihypertensive medication exclusion criteria: more than one antihypertensive medication refuse consent to review medical record pregnant prisoners

Keywords: behavior change patient education
efficacy and safety of valsartan and amlodipine (± hctz) in adults with moderate, inadequately controlled hypertension

Conditions: Hypertension

Summary: this study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension. there was an optional study extension for eligible patients who wanted to participate that contains the triple therapy (ie, hydrochlorothiazide+ amlodipine/valsartan).

title of study extension: an open-label, multicenter extension to evaluate the efficacy and tolerability of a 4 week therapy with hydrochlorothiazide 12.5 mg plus amlodipine 10 mg/valsartan 160 mg in hypertensive patients not adequately responding to a 4 week therapy each with the combinations of olmesartan 20 mg plus amlodipine 10 mg followed by amlodipine 10 mg/valsartan 160 mg

Eligibility criteria:
inclusion criteria for core study: * male or female patients (\>=18 years) * females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods * patients with essential hypertension (diastolic blood pressure \>=100 mmhg and \<110 mmhg) inclusion criteria for extension: - patients had to have a mssbp \>= 140 mmhg and/or msdbp \>= 90 mmhg at week 8 ie, end of core study. exclusion criteria for core study: * severe hypertension (diastolic blood pressure \>=110 mmhg or systolic blood pressure \>= 180 mmhg) * pregnant or nursing women * treated hypertensive patients with controlled hypertension under current therapy * a history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure nyha ii - iv exclusion criteria for extension: * prematurely discontinued the core study * failed to comply with the core study protocol other protocol-defined inclusion/exclusion criteria applied to the study.

Keywords: hypertension, valsartan, amlodipine
a study about how well tak-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 60 weeks of treatment with a withdrawal and retreatment period

Conditions: Plaque Psoriasis

Summary: the main aim of this study is to show how well tak-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. participants will be assigned to one of the 3 study treatments (tak-279, apremilast (an approved treatment), or a placebo). participants will be in the study for up to 69 weeks.

the drug being tested in this study is called tak-279. tak-279 is being tested to treat people with moderate to severe plaque psoriasis. the study will enroll approximately 1000 patients. participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups for tak-279, placebo, or apremilast in a ratio of 2:1:1 which will remain undisclosed to the patient and investigator during the study (unless there is an urgent medical need): * tak-279 * apremilast * placebo this multi-center trial will be conducted worldwide. the overall time to participate in this study is 69 weeks. participants will go through a screening process to make sure they meet the rules for taking part in the study. this will take up to 35 days. if participants meet the study rules, they will be treated for up to 60 weeks. there will be a safety follow-up visit 4 weeks after their last day of treatment.

Eligibility criteria:
inclusion criteria: 1. plaque psoriasis for at least 6 months. 2. moderate to severe disease. 3. candidate for phototherapy or systemic therapy. exclusion criteria: 1. other forms of psoriasis. 2. history of recent infection. 3. prior exposure to tak-279 or active comparator. other protocol defined inclusion/exclusion criteria apply.

Keywords: drug therapy latitude psoriasis 2, latitude research program
pain killer, anxiety and mucogingival therapy

Conditions: Anxiety and Depression

Summary: is the pain killer consumption after gingival treatment related to the level of patient anxiety or to the type of therapy?

anxiety and depression (had) scale used could be reveal the level of the patient anxiety and/or depression before intervention. additionnaly the use of these specific questionnaires (7 items for anxiety, 7 items for depression) could reveal if the pain killer consumption after gingical treatment is dependant to the level of had or to the therapy . this tool (had) could allows to recognize, before any (oral)surgery, profil with high risk and propose solution to decrease anxiety and/or depression before treatment.

Eligibility criteria:
inclusion criteria: * asa type i and ii subjects * localized gingival recessions * recessions cairo rt i-ii * fmps \< 10% * fmbs\< 10% * \<10 cigs/ day * no contra-indication against oral surgical interventions * patient is able to give inform consent exclusion criteria: * infection (local or systemic). each infection will be evaluated prior to study procedure for suitability. patients with gingivitis or local infection (fracture, apical reaction) will undergo a dental treatment prior to his entrance to the study. in case of systemic infection, the evaluation will be based on medical anamneses, and if necessary will be referred to relevant medical tests. * asa type \> ii * current pregnancy or breastfeeding women * alcoholism or chronically drug abuse * smokers, ≳ 10 cigarettes per day * immunocompromised patients * uncontrolled diabetes * untreated periodontitis * history of previous periodontal surgery (mucogingival or other) on the teeth to be included * presence of severe tooth malposition, rotation or significant version of the tooth to be treated
er,cr:ysgg laser for recipient bed bio-modification and connective tissue harvesting in treatment of gingival recession

Conditions: Gingival Recession, Localized

Summary: a clinical and radiographic evaluation of using erbium, chromium, scandium, gallium and garnet (er,cr:ysgg) laser in recipient site bio-modification and de-epithelialized connective tissue graft harvesting compared to conventional scalpel surgical technique in the treatment of class i and ii miller gingival recession.

twenty four patients suffering from isolated class i and ii miller gingival recession defects in anterior esthetic region were enrolled in this study. they were randomly assigned into three groups; de-epithelialized connective tissue graft harvesting technique or; conditioning the exposed root surfaces with er,cr:ysgg laser before connective tissue coverage using scalpel blade harvested de-epithelialized connective tissue graft harvesting technique, or; conditioning the exposed root surfaces with the er,cr:ysgg laser before er,cr:ysgg laser harvested connective tissue using de-epithelialized technique. clinical and radiographic parameters were recorded at baseline and at 3, 6 and 9 months postoperatively.

Eligibility criteria:
inclusion criteria: 1. single class i, ii miller gingival recession defects (≥ 2mm in depth), presence of identifiable buccal cemento-enamel junction (cej) and presence of a step ≤ 1 mm at cej. 2. controlled periodontal disease 3. full-mouth plaque score of \<10%; full-mouth gingival score of \<15% 4. patients available for 9 months follow-up period. exclusion criteria: 1. smokers. 2. pregnant and lactating females. 3. taking medications known to interfere with periodontal tissue health or healing. 4. previous periodontal surgery on the involved sites. 5. non-vital teeth. 6. molar teeth. 7. recession defects associated with caries or restoration. 8. occlusal interferences. 9. taking anti-inflammatory drugs or antibiotics in the past 6 months.

Keywords: er,cr:ysgg laser connective tissue graft root coverage mucogingival surgery gingival recession
pacific-cup classifies cancer of unknown primary

Conditions: Unknown Primary Tumors; DNA Methylation

Summary: this study aims to initially utilize machine learning on pan-cancer dna methylation data from public databases to construct a dna methylation classification model (pacific-cup, pan-cancer integrated fingerprinting classifier of cup) for diagnosing various types of cancer, particularly the primary site of cancer of unknown primary. the goal is to achieve diagnosis of cancer pathology type by analyzing the dna methylation patterns of cancer specimens, thereby guiding subsequent precision treatment for cancer.


Eligibility criteria:
inclusion criteria: 1. the patient specimens were obtained from the sun yat-sen university cancer center and affiliated cooperating centers, with written consent from the patients authorizing the use of the specimens for research purposes. 2. following standard assessments (medical history, physical examination, complete blood count, biochemistry, computed tomography scans of the neck, chest, abdomen, and pelvis, targeted evaluations of all symptomatic areas, pathology, and immunohistochemistry), the diagnosis was determined as a primary site unknown tumor (including adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, sarcoma, etc). 3. the diagnosis was confirmed at the participating institution and the patient had received systemic therapy. 4. complete clinical, pathological, and follow-up data for the patients can be obtained. 5. ecog performance status score: 0-2 points. exclusion criteria: 1. pregnant or lactating female patients. 2. tumor tissue sample size is too small (tumor tissue accounts for \<70% in the biopsy or slice tissue). 3. organ transplant or history of non-autologous (allogeneic) bone marrow or stem cell transplantation. 4. history of previous tumors, with the current condition being a recurrent tumor. 5. hematological malignancies (excluding lymphoma). 6. other diseases that may severely impact patient survival, such as severe cardiovascular or cerebrovascular diseases, sepsis, severe trauma or burns, etc.

Keywords: unknown primary tumors dna methylation large language model pan-cancer